Register Now - Beyond Recruitment: The Future of Patient Site Engagement in Oncology Clinical Trials
|Events|April 19, 2023

Outsourcing In Clinical Trials Southern California 2023 (9/26 - 9/27/23)

About Arena International:

Arena International Events Group (part of GlobalData) brings together sponsors and delegates in a way that maximises business outcomes and professional standing, by providing uncompromised value rooted in business intelligence. Simply put, we design and produce events that add tangible value for attendees, through education/learning programmes, exhibitions, and extensive networking opportunities.

Our annual healthcare conferences welcome 6,000+ senior-level pharmaceutical, biotech and medical device executives and other health experts to facilitate positive changes, exchange ideas and stay up to date with shifting trends and practices.

About our events:

What our Outsourcing Clinical Trial events series offer:

Our content-rich conference will provide delegates with the opportunity to develop practical strategies for refining their outsourcing strategy and overall clinical trial management. For the 13th time, we are bringing our OCT global series to Europe and inviting decision makers from small, medium, and large pharma and medical device companies to help advance your clinical trial within timelines and budget while keeping each patient as a priority.

September 26-27, 2023

Hyatt Regency La Jolla at Aventine

https://www.arena-international.com/event/octsocal/



Related to this article

Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health
In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.
© Grispb - © Grispb - stock.adobe.com
Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.
The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.